| ACLT | anterior cruciate ligament transection |
| CIA | collagen-induced arthritis |
| COX-2 | cyclooxygenase-2 |
| DMARDs | disease-modifying antirheumatic drugs |
| EO | essential oil |
| FCA | Freund’s complete adjuvant |
| FDA | Food and Drug Administration |
| IFN-γ | interferon-γ |
| IL-1β | interleukin-1β |
| IL-6 | interleukin-6 |
| iNOS | inducible nitric oxide synthase |
| JAK/STAT | Janus kinase/signal transducer and activator of transcription |
| LPS | lipopolysaccharide |
| MMPs | matrix metalloproteinases |
| MSU | monosodium urate |
| Mtb | M. tuberculosis |
| NLRP3 | NOD-, LRR-, and pyrin-domain-containing 3 |
| NO | nitric oxide |
| NSAIDs | non-steroidal anti-inflammatory drugs |
| OA | osteoarthritis |
| PGE2 | prostaglandin E2 |
| RA | rheumatoid arthritis |
| SCW | streptococcal cell wall |
| SF | synovial fluid |
| SIC | synovium-infiltrating cells |
| SW982 | human synovial cell line |
| TGF | tumor growth factor |
| TIMPs | tissue inhibitors of metalloproteinases |
| TNF-α | tumor necrosis factor |